Saltar al contenido principal
World Congress on Medical Oncology
Olympic Paris 2024
Test 4
Test 1
Test 2
Test 5
Test 3
Test clone mv
Olympic Paris 2024
Olympic Paris 2024 - VIP - Boss Ticket
Olympic Paris 2024
Finance Code Test
Concrete Institute of Australia’s Biennial National Conference 2025
Concrete Institute of Australia’s Biennial National Conference 2025
Test Goldenowl Conference
Virtual Event 01
Paris Olypmpic Clone 12.09 webinar
7th World Congress of Nanoentomology
NDS NAB Transact testing
JC test 01
Pre-Release 3 Oct
DEX (Digital Employee Experience) conference 2024
test derek
TimeZone Test
TimeZone Test
Talent Events
Event Demo
Olympic Paris 2024 x
original event name for cloning testing
Olympic Paris 2024
Default payment method test
evexus Event - 509
Default payment method test2
Test Worker
Test Worker
charlie test
Arinex 1
NET24 Ho Chi Minh City Workshop 2024
Telefilm 2024 - International Exhibition of Film and Television Technology in Vietnam
Olympic Paris 2024
charlie test 2711
charlie test 2711 cloned
CICM SecurePay testing
The AI Submit 2024
Test webinar 04.12 - - - -
Taylor Swift Clone 04
Taylor Swift Clone 02
Taylor Swift
Taylor Swift Clone
Taylor Swift Clone 01
Import Test
The Trading Summit 2024 (HCM - Vietnam)
Electric Dreams: A Synthwave Extravaganza
Taylor Swift 16
Taylor Swift 12
Taylor Swift 14
Taylor Swift 15
Taylor Swift 17
Taylor Swift 20
Coin Based Hackathon 2024
Rose 01
Import Ticket
Vu Cat Tuong
STEM 1
Kids STEM
CLONE Innovate 2025: A Future Forward Summit
Innovate 2025: A Future Forward Summit
Petals & Sunshine Festival
webinar 05/02
Science
evexus Event - 273
evexus Event - 275
Association webinar 5.2
evexus Event - 274
Aurora Nights 2025 - Webinar
Seoul AI Seminar
Webinar Event - Lily AI - 20/02
evexus Event - 287
Taylor Swift 11
Swifties Only Social Contact
cloned event for Bree QA
evexus Event - 288
evexus Event - 289
Bree QA event
Tim's event
Ralph's event
Tim cloned enable all
Ralph clone event the last one
Hawaii AI Seminar
evexus Event - 293
Tokyo Seminar
Indiana AI Seminar
Registration ticket 2025
TechNova Summit
Event - 28 - 03 - 2025
TechNova Summit [2]
TechNova Summit [3]
Tech v1
Event 28/03/2025
Job Affairs
Fan Job
Webinar Event - Lily AI - 04/03
Event Registration
Association webinar 20.2
Fan's stock query
Registration
Aurora Nights 2025
Ralph test email
Taylor Swift 13
The Core 2025
Rose
The Thirdweb submit
Stress Test Conference 2026
Alan'event
World Congress of Medical Oncology
The AI Seoul Submit 2026
The Core 2026
Los horarios se muestran en su zona horaria local GMT
Endo-ACE: a five-year single-centre audit of endoscopic ultrasound-guided gallbladder drainage outcomes and factors influencing patient selection
Verbal Presentation

Verbal Presentation

3:20 pm

15 August 2026

Bellevue Ballroom 2

Biliary Complexities

Talk Descripción

Institución: Monash Health - Victoria, Australia

Purpose: Laparoscopic cholecystectomy remains the standard of care for acute cholecystitis; however, a subset of patients is unsuitable for surgery due to frailty, significant comorbidity, hostile anatomy, or advanced malignancy. Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) using a lumen-apposing metal stent offers a minimally invasive alternative. This study reports clinical outcomes of EUS-GBD and characterises the preoperative factors influencing patient selection. Methodology: A retrospective single-centre audit was performed of all EUS-GBD procedures undertaken between 2020 and 2024 at a tertiary hospital in Melbourne, Australia. All procedures were performed by experienced endoscopists using lumen-apposing metal stents (AXIOS™). Demographic, clinical, and outcome data were collected. Preoperative risk was assessed using the Clinical Frailty Scale (CFS), Charlson Comorbidity Index (CCI), Karnofsky Performance Scale, and the ACS NSQIP surgical risk calculator. Results: Thirty-five patients (median age 75 years) underwent EUS-GBD. Technical success was achieved in 33/35 patients (94%), with clinical symptom resolution in 30/35 (86%). Ninety-day mortality was 26% (n=9); all deaths occurred in patients with metastatic or locally advanced malignancy. Only one patient (3%) required readmission for recurrent acute cholecystitis within 90 days. The majority of patients had active malignancy (20/35). Median CFS was 5 (IQR 4–5), median CCI was 6 (IQR 2–8), and median Karnofsky score was 70 (IQR 55–90). Sixty per cent had a NSQIP-predicted mortality exceeding 10% for laparoscopic cholecystectomy. Patients with higher functional status were selected primarily due to hostile anatomy. Conclusion: EUS-GBD is a safe and effective alternative for high-risk patients with acute cholecystitis, demonstrating high technical and clinical success with low recurrence. Current surgical risk tools broadly align with clinician judgement in patient selection; however, prospective trial data is required to help develop a dedicated framework.
Speakers
Contributors
Authors

Dr Joseph Jaya - , Dr Ashwin Rajagopalan - , Dr Georgina Riddiough - , Dr James Wilkinson - , Dr Sidhartha Gupta - , Dr Michael Swan - , Dr Geraldine Ooi - , Dr Daniel Croagh -

Otro Sugerido Talks
Privacy Statement Header

By confirming your acceptance below, you agree to our Privacy Policy